Type 2 Diabetes
Conditions
Keywords
Tesaglitazar, type 2 diabetes
Brief summary
This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 2-week enrollment period, 4 week placebo single blind run in period followed by a 12-week double blind treatment period and a 3-week follow-up period
Interventions
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Provision of a written informed consent * Men or women who are 30 to 80 years of age * Female patients: postmenopausal or surgically sterile * Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL * Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
Exclusion criteria
* Type 1 diabetes * New York Heart Association heart failure Class III or IV * Treatment with chronic insulin * History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists. * History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) * Creatinine levels above 1.2 mg/dL * Received any investigational product in other clinical studies within 30 days * Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute change from baseline to end of randomized treatment period in fasting plasma glucose (FPG) | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in plasma glucose and insulin during an oral glucose tolerance test | — |
| Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model | — |
| Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids | — |
| Change in insulin levels and hemoglobin A1c (HbA1c) levels | — |
| Changes in the following variables from baseline to the end of the randomized treatment period: | — |
| Pharmacokinetics of tesaglitazar | — |
| To assess the burden of type 2 diabetes mellitus in patients through the administration of the SF-36 health survey and the Well-Being Questionnaire (W BQ12) and comparing the study population data to published national and international normative data | — |
| To evaluate diabetes-specific instruments, Audit of Diabetes Dependent Quality of Life (ADDQoL) and The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (s and c) in the study population and estimate the effect size of the instruments in patients r | — |
| Responder analyses for FPG, TG, and HDL C according to pre-specified values | — |
Countries
Canada, France, Mexico, United States
Outcome results
None listed